Verve Therapeutics(VERV)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VERV Verve Therapeutics

交易中 07-22 15:23:41 EDT

7.16

+0.27

+3.85%

最高7.17	最低6.76	成交量47.11万
今开6.99	昨收6.89	日振幅5.88%
总市值6.01亿	流通市值4.49亿	总股本8,397万
成交额326.03万	换手率0.75%	流通股本6,281万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"VERV","market":"US","secType":"STK","nameCN":"Verve Therapeutics","latestPrice":7.155,"timestamp":1721676219262,"preClose":6.89,"halted":0,"volume":471075,"delay":0,"floatShares":62806667,"shares":83965493,"eps":-2.831602,"marketStatus":"交易中","marketStatusCode":2,"change":0.265,"latestTime":"07-22 15:23:41 EDT","open":6.99,"high":7.165,"low":6.76,"amount":3260320.62708,"amplitude":0.058781,"askPrice":7.16,"askSize":883,"bidPrice":7.15,"bidSize":841,"shortable":3,"etf":0,"ttmEps":-2.831602,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1721678400000},"adr":0,"listingDate":1623902400000,"adjPreClose":6.89,"preHourTrading":{"tag":"盘前","latestPrice":6.98,"preClose":6.89,"latestTime":"09:29 EDT","volume":512,"amount":3636.6523392,"timestamp":1721654999999},"postHourTrading":{"tag":"盘后","latestPrice":6.8881,"preClose":6.89,"latestTime":"19:44 EDT","volume":3247,"amount":22285.6572,"timestamp":1721432665942},"volumeRatio":0.378287,"impliedVol":2.2698,"impliedVolPercentile":0.9602},"requestUrl":"/m/hq/s/VERV/tweets","defaultTab":"tweets","newsList":[{"id":"2426343169","title":"美国研究综述-阿波罗、特斯拉、UDR","url":"https://stock-news.laohu8.com/highlight/detail?id=2426343169","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2426343169?lang=zh_cn&edition=full","pubTime":"2024-04-10 14:51","pubTimestamp":1712731906,"startTime":"0","endTime":"0","summary":"    路透社4月10日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括阿波罗、特斯拉和 UDR。要闻             * 阿波罗  ：杰富瑞将目标价从112美元上调至119美元             * 特斯拉  ：杰富瑞将目标价从185美元下调至165美元             * UDR Inc   ：Piper Sandler将其评级从 \"减持 \"上调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APO","BK4535","BXMT","LU0006061336.USD","LU1551013425.SGD","STWD","LU0097036916.USD","IE00B19Z4B17.USD","NOW","LW","ACAD","KREF","LU0980610538.SGD","LU2264538146.SGD","CHK","KKR","WDFC","ACRE","DCGO","OLMA","BK4566","LU1668664300.SGD","ABR","LU1917777945.USD","OMI","VERA","VERV","LU0011850046.USD","LU0354030438.USD","LU0354030511.USD","LU1935042991.SGD","CG","LU1720051017.SGD","UDR","LU0943347566.SGD","BK4533","LU2249611893.SGD","TRTX","LU1861559042.SGD","LU2357305700.SGD","BK4097","LU1201861249.SGD","CMTG","TPG","TWO","ARI","BK4175","TSLA","TLRY","TSLL"],"gpt_icon":0},{"id":"2424001941","title":"暴跌36%！Verve Therapeutics旗下基因编辑试验因安全问题暂停","url":"https://stock-news.laohu8.com/highlight/detail?id=2424001941","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2424001941?lang=zh_cn&edition=full","pubTime":"2024-04-02 20:52","pubTimestamp":1712062345,"startTime":"0","endTime":"0","summary":"智通财经获悉，Verve Therapeutics的股价在盘前交易中暴跌，此前该公司表示，出于安全考虑，暂停了一项针对高胆固醇患者的基因编辑治疗研究的注册，这给前景光明的新医学领域带来了挫折。Verve在周二的一份声明中表示，该研究已获得英国和加拿大监管机构的临床试验许可，预计将于今年第二季度开始。这一消息对Verve来说是一个挫折，该公司旨在通过改变胆固醇升高基因来创造一种一次性治疗方法来预防心脏病发作。","market":"us","thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1098051.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","VERV","BK4539"],"gpt_icon":1},{"id":"2424701578","title":"BUZZ-Verve Therapeutics 暂停基因编辑疗法研究注册后业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2424701578","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2424701578?lang=zh_cn&edition=full","pubTime":"2024-04-02 19:51","pubTimestamp":1712058662,"startTime":"0","endTime":"0","summary":"    4月2日 - ** 基因药物公司Verve Therapeutics  股价盘前下跌33.5%至8.50美元 ** 该公司将暂停其名为VERVE-101的基因编辑疗法早期研究的 ，因为一名参与该研究的患者出现了严重的药物相关不良事件。** 该患者在服用 VERV-101 后的头四天内，体内一种致病肝酶水平升高，血小板水平异常降低。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","LENZ","VERV","BUZZ"],"gpt_icon":0},{"id":"2424097241","title":"Verve Therapeutics 暂停高胆固醇早期基因疗法研究的注册工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2424097241","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2424097241?lang=zh_cn&edition=full","pubTime":"2024-04-02 19:00","pubTimestamp":1712055611,"startTime":"0","endTime":"0","summary":"    路透社4月2日 - Verve Therapeutics   周二表示，在一名患者出现严重的药物相关不良事件后，该公司暂停了一项测试其治疗高胆固醇的实验性基因编辑疗法的早期研究的注册工作。该公司正在一种导致高胆固醇水平的遗传病患者中测试这种疗法，高胆固醇水平会增加患心脏病的风险。这种疗法可以永久性地关闭一种叫做 PCSK9 的蛋白质，帮助降低血液中的胆固醇水平。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERV","LENZ","BK4139","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vervetx.com","stockEarnings":[{"period":"1week","weight":0.0238},{"period":"1month","weight":0.351},{"period":"3month","weight":0.0377},{"period":"6month","weight":-0.4229},{"period":"1year","weight":-0.6525},{"period":"ytd","weight":-0.5057}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Verve Therapeutics, Inc.于2018年3月9日成立为特拉华州公司。他们是一家基因药物公司，开创了一种治疗心血管疾病或CVD的新方法，将治疗从慢性管理转变为单程基因编辑药物。他们认为，单疗程治疗可以为患有动脉粥样硬化性心血管疾病或ASCVD或有患动脉粥样硬化性心血管疾病风险的患者提供终生持续的显著健康益处。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.088813},{"month":2,"riseRate":0.666667,"avgChangeRate":0.181282},{"month":3,"riseRate":0,"avgChangeRate":-0.254413},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.262971},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.049534},{"month":6,"riseRate":0.666667,"avgChangeRate":0.053142},{"month":7,"riseRate":0.75,"avgChangeRate":0.275583},{"month":8,"riseRate":0.666667,"avgChangeRate":0.121126},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.13414},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.002486},{"month":11,"riseRate":0,"avgChangeRate":-0.237434},{"month":12,"riseRate":0.666667,"avgChangeRate":0.050219}],"exchange":"NASDAQ","name":"Verve Therapeutics","nameEN":"Verve Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Verve Therapeutics(VERV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Verve Therapeutics(VERV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Verve Therapeutics,VERV,Verve Therapeutics股票,Verve Therapeutics股票老虎,Verve Therapeutics股票老虎国际,Verve Therapeutics行情,Verve Therapeutics股票行情,Verve Therapeutics股价,Verve Therapeutics股市,Verve Therapeutics股票价格,Verve Therapeutics股票交易,Verve Therapeutics股票购买,Verve Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Verve Therapeutics(VERV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Verve Therapeutics(VERV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况